A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study
- PMID: 30971214
- PMCID: PMC6458687
- DOI: 10.1186/s12884-019-2266-y
A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study
Abstract
Background: To compare the rates of adverse pregnancy outcomes between women with normal and abnormal inhibin-A levels.
Methods: Based on a prospective database of Down syndrome screening program, the consecutive records were comprehensively reviewed. Pregnancies were classified into three groups: normal, high (> 2 MoM) and low (< 0.5 MoM) inhibin-A levels. The pregnancies with medical diseases, chromosome abnormalities and fetal anomalies were excluded. The primary outcomes were the rates of preterm birth, preeclampsia, and fetal growth restriction (FGR).
Results: Of 6679 recruited pregnancies, 5080 met the inclusion criteria, including 4600, 205 and 275 pregnancies in the group of normal, high, and low inhibin-A levels respectively. The rates of preterm birth, preeclampsia and FGR were significantly higher in the group of high levels; (RR, 1.51, 95%CI: 1.01-2.26; 3.47, 95% CI: 2.13-5.65; 3.04, 95% CI: 1.99-4.65 respectively), whereas the rates of other adverse outcomes were comparable. However, the rate of spontaneous preterm birth among women with high inhibin-A was not significantly increased. Based on multivariate analysis, the preterm birth rate was not significantly associated with inhibin-A levels, but it was rather a consequence of preeclampsia and FGR. Low levels of serum inhibin-A were not significantly associated with any adverse outcomes.
Conclusions: High levels of maternal serum inhibin-A in the second trimester are significantly associated with abnormal placentation, which increases the risk of preeclampsia and FGR with a consequence of indicated preterm birth but not a risk of spontaneous preterm birth. In contrast, low inhibin-A levels were not associated with any common adverse pregnancy outcomes.
Keywords: Fetal growth restriction; Inhibin-a; Preeclampsia; Preterm birth; Serum marker screening.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Institutional Review Boards; The Research Ethics Committee 4; Faculty of Medicine, Chiang Mai University. Study code: OBG-2560-04899/ Research ID: 4899.
All participants were recruited with written informed consent.
Consent for publication
The Informed Consent Forms which all participants signed included consent for publication of their data. Data were de-identified after collection and participants were allocated codes for analysis and pseudonyms for publication.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome?PLoS One. 2020 May 29;15(5):e0232634. doi: 10.1371/journal.pone.0232634. eCollection 2020. PLoS One. 2020. PMID: 32469905 Free PMC article.
-
Association between isolated abnormal levels of maternal serum unconjugated estriol in the second trimester and adverse pregnancy outcomes.J Matern Fetal Neonatal Med. 2016;29(13):2093-7. doi: 10.3109/14767058.2015.1075503. Epub 2015 Aug 28. J Matern Fetal Neonatal Med. 2016. PMID: 27480207
-
Obstetrical complications associated with abnormal maternal serum markers analytes.J Obstet Gynaecol Can. 2008 Oct;30(10):918-932. doi: 10.1016/S1701-2163(16)32973-5. J Obstet Gynaecol Can. 2008. PMID: 19038077 Review. English, French.
-
Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes.J Obstet Gynaecol Can. 2015 Feb;37(2):111-6. doi: 10.1016/s1701-2163(15)30331-5. J Obstet Gynaecol Can. 2015. PMID: 25767942
-
Clinical application of inhibin a measurement: prenatal serum screening for Down syndrome.Semin Reprod Med. 2004 Aug;22(3):235-42. doi: 10.1055/s-2004-831899. Semin Reprod Med. 2004. PMID: 15319826 Review.
Cited by
-
Evaluation of first trimester maternal serum inhibin-A for preeclampsia screening.PLoS One. 2023 Jul 10;18(7):e0288289. doi: 10.1371/journal.pone.0288289. eCollection 2023. PLoS One. 2023. PMID: 37428792 Free PMC article.
-
Association Between Serum Markers Used in the Routine Prenatal Screening with Pregnancy Outcomes: A Cohort Study.J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):6-18. doi: 10.1007/s13224-021-01508-8. Epub 2021 Aug 6. J Obstet Gynaecol India. 2022. PMID: 35928095 Free PMC article.
-
Altered Thermal Behavior of Blood Plasma Proteome Related to Inflammatory Cytokines in Early Pregnancy Loss.Int J Mol Sci. 2022 Aug 6;23(15):8764. doi: 10.3390/ijms23158764. Int J Mol Sci. 2022. PMID: 35955896 Free PMC article.
-
Placental biomarkers in second trimester maternal serum are associated with postpartum hemorrhage: a secondary analysis of the NuMoM2b dataset.medRxiv [Preprint]. 2025 Jan 2:2024.12.30.24319779. doi: 10.1101/2024.12.30.24319779. medRxiv. 2025. PMID: 39802772 Free PMC article. Preprint.
-
Endocrine and metabolic interactions in healthy pregnancies and hyperinsulinemic pregnancies affected by polycystic ovary syndrome, diabetes and obesity.Front Endocrinol (Lausanne). 2023 Jan 17;13:993619. doi: 10.3389/fendo.2022.993619. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36733795 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous